| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST30: Sebelipase alfa for treating Wolman disease |
|
Medicine details |
|
| Medicine name | sebelipase alfa (Kanuma®) |
| Formulation | 2 mg/ml concentrate for solution for infusion |
| Reference number | 1305 |
| Indication | For long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency |
| Company | Alexion Pharma UK Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/12/2021 |
| NICE guidance | |
| Further information Initial FED ID737 for lysosomal acid lipase deficiency was not recommended. NICE appraising for Wolman disease population as ID3995 (14/12/2021) |
|